Statistics

Total Visits

Views
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): A multicentre, open-label, randomised phase 3 trial59

Select a period of time:

Number of views in the range

Views
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): A multicentre, open-label, randomised phase 3 trial39

Views

Views
March 202516
April 20255
May 20251
June 20251
July 202512
August 20253
September 20251
Download CSV file
 untranslated
 untranslated

Top country views

Views
Singapore16
United States9
Brazil7
Mexico2
Germany1
Spain1
United Kingdom1
Uruguay1
Venezuela1
 

Top cities views

Views
São Paulo2
Phoenix2
Altinópolis1
Barueri1
Brooklyn1
Cordova1
Council Bluffs1
Culiacán1
Dallas1
Garopaba do Sul1